Physicochemical Properties
| Molecular Formula | C212H316F3N57O59S |
| Molecular Weight | 4696.18 |
| Related CAS # | Adrenocorticotropic Hormone (ACTH) (1-39), rat;77465-10-2 |
| Appearance | Solid powder |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | At doses between 100 and 400 nM, ACTH 1-39 exhibits no toxic effects on neurons; however, it offers protection against excitotoxic neuronal death caused by glutamate (100 μM), NMDA (1 mM), AMPA (50 μM), and kainate (25 μM). In every situation, significant protection is offered by ACTH at 400 nM. Neurons are shielded against quinolinic acid (25 μM) by ACTH at 200 or 400 nM. Moreover, 2 μM H2O2, which produces reactive oxygen species (ROS), induces cell death that is prevented by ACTH; at 400 nM ACTH, there is noticeably greater protection than at 200 nM. While ACTH does not prevent gradual release of nitric oxide (NO) by NOC-18, it does provide some protection against the fast production of NO by NOC-12. The classic inducer of cell death through apoptosis, staurosporine (10–20 nM), is cytotoxic to neurons. However, ACTH (200–400 nM) shields neurons from its effects. Cell death is reduced by ACTH from 80% to 55%[1]. |
| ln Vivo | In comparison to the saline/IgG group, the cumulative food consumption during the observation time is dramatically reduced by the icv injection of ACTH. The anorexigenic action of ACTH is eliminated when ACTH Ab is injected into the PVN. Rats receiving α-MSH Ab into the PVN and ACTH icv had much lower cumulative food consumption after ACTH infusion; in fact, food intake is the same as in the group treated with ACTH icv and IgG into the PVN. When injecting either ACTH Ab or α-MSH Ab into PVN, the animals' cumulative food intake increases dramatically when compared to IgG-treated mice; however, applying both Ab together does not result in a greater rise in food intake[2]. |
| References |
[1]. Melanocortin receptor agonist ACTH 1-39 protects rat forebrain neurons from apoptotic, excitotoxic and inflammation-related damage. Exp Neurol. 2015 Nov;273:161-7. [2]. Endogenous ACTH, not only alpha-melanocyte-stimulating hormone, reduces food intake mediated by hypothalamic mechanisms. Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E237-44. |
Solubility Data
| Solubility (In Vitro) | H2O :~100 mg/mL (~21.29 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2129 mL | 1.0647 mL | 2.1294 mL | |
| 5 mM | 0.0426 mL | 0.2129 mL | 0.4259 mL | |
| 10 mM | 0.0213 mL | 0.1065 mL | 0.2129 mL |